Peyronie’s disease: new paradigm for the treatment of a unique cause of erectile dysfunction

4

ABSTRACT

Peyronie’s Disease is an incurable condition of the tunica albuginea of the penis associated with scarring, plaque formation, and penile deformity on erection. It is often associated with erectile dysfunction. Recent data have supported a familial and genetic predisposition to this chronic condition. The etiology of Peyronie’s Disease is unknown, but is likely associated with multiple micro traumas to the erect penis in men who are susceptible to the scarring typical of Peyronie’s Disease. The treatment of Peyronie’s Disease has improved over the past decade as a result of animal studies and the approval of new medications. In the acute phase of the condition, phosphodiesterase type 5 inhibitors have been shown to have some benefit and are supported by animal studies demonstrating reduced fibrosis of the penis in animal models of Peyronie’s Disease. In the stable phase of the disease, newer injectable agents have shown great promise. Collagenase clostridium histolyticum is approved for the treatment of Peyronie’s plaques by direct injection into the scarred tissue with data showing satisfactory safety and efficacy. Surgical procedures for penile straightening have been refined with improved outcomes in the past decade. For those men with erectile dysfunction and Peyronie’s Disease, penile implants can restore erectile function and form. As a result of the new understanding of the risk factors for Peyronie’s Disease and recent advances in treatment options, the algorithm for the treatment of Peyronie’s Disease has improved outcomes for patients and their partners.

KEYWORDS:

• Mens health
• Peyronie’s disease
• fibrosis
• plaque

Declaration of interest

The contents of the paper and the opinions expressed within are those of the authors, and it was the decision of the authors to submit the manuscript for publication.

Reviewer disclosures

A reviewer on this manuscript has disclosed they are a speaker’s bureau for Endo Pharmaceuticals. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.